• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成年人减肥药物的药物遗传学相互作用:系统评价和荟萃分析。

Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.

机构信息

Clinical Enteric Neuroscience Translational & Epidemiological Research (CENTER), Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN 55905, USA.

Library, Public Service Department, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Pharmacogenomics. 2023 Apr;24(5):283-295. doi: 10.2217/pgs-2022-0192. Epub 2023 Mar 31.

DOI:10.2217/pgs-2022-0192
PMID:36999540
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10152409/
Abstract

To analyze roles of single nucleotide variants (SNVs) on weight loss with US FDA-approved medications. We searched the literature up until November 2022. Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines were followed. 14 studies were included in qualitative analysis and seven in meta-analysis. SNVs in , , , , , , and were evaluated relative to weight loss with glucagon-like peptide-1 agonists (13 studies) or naltrexone-bupropion (one study). gene (rs1049353), gene (rs6923761, rs10305420), gene (rs7903146) were associated with weight loss in at least one study involving glucagon-like peptide-1 agonist(s). The meta-analysis did not identify any consistent effect of SNVs. Pharmacogenetic interactions for exenatide, liraglutide, naltrexone-bupropion and weight loss were identified, but the directionality was inconsistent.

摘要

分析美国食品和药物管理局批准的药物治疗体重减轻的单核苷酸变异(SNV)的作用。我们检索了截至 2022 年 11 月的文献。遵循系统评价和荟萃分析的首选报告项目指南。14 项研究进行了定性分析,7 项进行了荟萃分析。评估了与胰高血糖素样肽-1 激动剂(13 项研究)或纳曲酮-安非他酮(一项研究)相关的 、 、 、 、 、 基因(rs1049353)、 基因(rs6923761、rs10305420)、 基因(rs7903146)中的 SNV 与体重减轻的关系。至少有一项涉及胰高血糖素样肽-1 激动剂的研究表明, 基因(rs1049353)、 基因(rs6923761、rs10305420)和 基因(rs7903146)中的 SNV 与体重减轻有关。荟萃分析没有发现 SNV 的任何一致影响。确定了 exenatide、liraglutide、naltrexone-bupropion 和体重减轻的药物遗传学相互作用,但方向性不一致。

相似文献

1
Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.成年人减肥药物的药物遗传学相互作用:系统评价和荟萃分析。
Pharmacogenomics. 2023 Apr;24(5):283-295. doi: 10.2217/pgs-2022-0192. Epub 2023 Mar 31.
2
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.胰高血糖素样肽-1 受体激动剂对体重减轻的影响:随机对照试验的系统评价和荟萃分析。
BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771.
3
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.二肽基肽酶(DPP)-4抑制剂和胰高血糖素样肽(GLP)-1类似物用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2.
4
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.长效胰高血糖素样肽-1 受体激动剂与艾塞那肽每日 2 次和西格列汀在 2 型糖尿病中的疗效和安全性比较:系统评价和荟萃分析。
Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5.
5
Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.胰高血糖素样肽-1受体激动剂反应的预测因素:一项随机对照试验的荟萃分析与系统评价
Acta Diabetol. 2017 Dec;54(12):1101-1114. doi: 10.1007/s00592-017-1054-2. Epub 2017 Sep 20.
6
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.新型 2 型糖尿病血糖控制药物:系统评价和经济评估。
Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360.
7
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.胰高血糖素样肽-1受体激动剂在2型糖尿病治疗中的疗效与安全性:一项系统评价和混合治疗比较分析
Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17.
8
Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂与基础胰岛素治疗2型糖尿病的比较:一项系统评价和荟萃分析。
Diabetes Obes Metab. 2017 Feb;19(2):228-238. doi: 10.1111/dom.12805. Epub 2016 Dec 5.
9
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.肠促胰岛素疗法治疗2型糖尿病的疗效与安全性:系统评价与荟萃分析
JAMA. 2007 Jul 11;298(2):194-206. doi: 10.1001/jama.298.2.194.
10
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].[2型糖尿病新型降糖药物:文献综述]
Ned Tijdschr Geneeskd. 2010;154:A886.

本文引用的文献

1
Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity.司美格鲁肽:一种有前途的治疗儿童罕见遗传性肥胖症的药物。
Curr Opin Endocrinol Diabetes Obes. 2023 Apr 1;30(2):136-140. doi: 10.1097/MED.0000000000000798. Epub 2023 Feb 1.
2
FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade.过去十年中获得美国食品药品监督管理局(FDA)批准的减肥药物疗法。
Cureus. 2022 Sep 17;14(9):e29262. doi: 10.7759/cureus.29262. eCollection 2022 Sep.
3
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.AGA 临床实践指南:药物干预成人肥胖症。
Gastroenterology. 2022 Nov;163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045. Epub 2022 Oct 20.
4
Precision Medicine for Obesity.肥胖症的精准医学
Dig Dis Interv. 2021 Sep;5(3):239-248. doi: 10.1055/s-0041-1729945.
5
Factors associated with successful weight loss after liraglutide treatment for obesity.与利拉鲁肽治疗肥胖症后成功减肥相关的因素。
Diabetes Obes Metab. 2023 Feb;25(2):377-386. doi: 10.1111/dom.14880. Epub 2022 Oct 24.
6
Association and interaction of the MC4R rs17782313 polymorphism with plasma ghrelin, GLP-1, cortisol, food intake and eating behaviors in overweight/obese Iranian adults.超重/肥胖伊朗成年人中 MC4R rs17782313 多态性与血浆 ghrelin、GLP-1、皮质醇、食物摄入和饮食行为的关联和相互作用。
BMC Endocr Disord. 2022 Sep 19;22(1):234. doi: 10.1186/s12902-022-01129-w.
7
Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial.利拉鲁肽对肥胖患者胃肠功能和体重的影响:一项随机临床和药物基因组学试验。
Obesity (Silver Spring). 2022 Aug;30(8):1608-1620. doi: 10.1002/oby.23481.
8
International lack of equity in modern obesity therapy: the critical need for change in health policy.现代肥胖症治疗在国际上缺乏公平性:卫生政策变革的迫切需求。
Int J Obes (Lond). 2022 Sep;46(9):1571-1572. doi: 10.1038/s41366-022-01176-2. Epub 2022 Jul 1.
9
Clinical and Genetic Predictors of Glycemic Control and Weight Loss Response to Liraglutide in Patients with Type 2 Diabetes.2型糖尿病患者血糖控制及利拉鲁肽减重反应的临床与遗传预测因素
J Pers Med. 2022 Mar 9;12(3):424. doi: 10.3390/jpm12030424.
10
Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study.中国2型糖尿病患者胰高血糖素样肽-1受体基因多态性与GLP-1受体激动剂治疗反应的关联:一项前瞻性队列研究
Eur J Clin Pharmacol. 2022 May;78(5):793-799. doi: 10.1007/s00228-021-03249-z. Epub 2022 Jan 25.